NO2865735T3 - - Google Patents

Info

Publication number
NO2865735T3
NO2865735T3 NO15151831A NO15151831A NO2865735T3 NO 2865735 T3 NO2865735 T3 NO 2865735T3 NO 15151831 A NO15151831 A NO 15151831A NO 15151831 A NO15151831 A NO 15151831A NO 2865735 T3 NO2865735 T3 NO 2865735T3
Authority
NO
Norway
Application number
NO15151831A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2865735T3 publication Critical patent/NO2865735T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
NO15151831A 2013-07-12 2012-03-29 NO2865735T3 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361845807P 2013-07-12 2013-07-12

Publications (1)

Publication Number Publication Date
NO2865735T3 true NO2865735T3 (cg-RX-API-DMAC7.html) 2018-07-21

Family

ID=51257630

Family Applications (1)

Application Number Title Priority Date Filing Date
NO15151831A NO2865735T3 (cg-RX-API-DMAC7.html) 2013-07-12 2012-03-29

Country Status (18)

Country Link
US (6) US9458159B2 (cg-RX-API-DMAC7.html)
EP (2) EP3019499B1 (cg-RX-API-DMAC7.html)
JP (1) JP6411492B2 (cg-RX-API-DMAC7.html)
AU (3) AU2014286995B2 (cg-RX-API-DMAC7.html)
CA (1) CA2918055C (cg-RX-API-DMAC7.html)
CY (1) CY1119545T1 (cg-RX-API-DMAC7.html)
DK (1) DK3019499T3 (cg-RX-API-DMAC7.html)
ES (2) ES2856867T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20171807T1 (cg-RX-API-DMAC7.html)
HU (1) HUE037343T2 (cg-RX-API-DMAC7.html)
LT (1) LT3019499T (cg-RX-API-DMAC7.html)
NO (1) NO2865735T3 (cg-RX-API-DMAC7.html)
PL (1) PL3019499T3 (cg-RX-API-DMAC7.html)
PT (1) PT3019499T (cg-RX-API-DMAC7.html)
RS (1) RS56539B1 (cg-RX-API-DMAC7.html)
SI (2) SI3252053T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201700525T1 (cg-RX-API-DMAC7.html)
WO (1) WO2015006733A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013361401C1 (en) 2012-12-21 2018-08-09 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP3019503B1 (en) * 2013-07-12 2017-09-06 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
NO2865735T3 (cg-RX-API-DMAC7.html) 2013-07-12 2018-07-21
EP3196201B1 (en) 2014-08-22 2021-04-28 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase-inhibiting activity
PH12021551982A1 (en) 2015-03-04 2022-09-05 Gilead Sciences Inc Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
PT3466490T (pt) * 2015-04-02 2020-12-24 Gilead Sciences Inc Compostos de carbamoilpiridona policíclicos e sua utilização farmacêutica
US20210292327A1 (en) 2015-08-26 2021-09-23 Gilead Sciences, Inc. Deuterated toll-like receptor modulators
AU2016322763A1 (en) 2015-09-15 2018-04-19 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of HIV
JP6621933B2 (ja) * 2015-11-09 2019-12-18 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルスを処置するための治療組成物
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
US10370342B2 (en) 2016-09-02 2019-08-06 Gilead Sciences, Inc. Toll like receptor modulator compounds
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
CN110526930B (zh) * 2018-05-23 2022-06-03 莫云芬 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
KR102741390B1 (ko) 2018-05-31 2024-12-10 시오노기 앤드 컴파니, 리미티드 다환성 카바모일피리돈 유도체
BR112020024098A2 (pt) 2018-05-31 2021-02-17 Shionogi & Co., Ltd. derivado de piridona policíclica
CR20210486A (es) 2019-03-22 2021-12-07 Gilead Sciences Inc Compuestos de carbamoyl piridona tricíclicos con puente y su uso farmacéutico
US20220305115A1 (en) 2019-06-18 2022-09-29 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
WO2021107066A1 (ja) 2019-11-28 2021-06-03 塩野義製薬株式会社 インテグラーゼ阻害剤及び抗ｈｉｖ薬を組み合わせることを特徴とするｈｉｖ感染症の予防及び治療用医薬
IL295677A (en) 2020-02-24 2022-10-01 Gilead Sciences Inc Tetracyclic compounds for treating hiv infection
WO2022072520A1 (en) * 2020-09-30 2022-04-07 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
JP7591155B2 (ja) 2021-01-19 2024-11-27 ギリアード サイエンシーズ， インコーポレイテッド 置換ピリドトリアジン化合物及びその使用
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE788516A (fr) 1971-09-10 1973-03-07 Lonza Ag Procede de fabrication d'esters alcoxyacetylacetiques
GB1528382A (en) 1974-12-26 1978-10-11 Teijin Ltd Cyclopentene diols and acyl esters thereof and processes for their preparation
DE2658401A1 (de) 1976-12-23 1978-07-06 Merck Patent Gmbh Cyclopentan-1-amine, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
US4575694A (en) 1984-03-05 1986-03-11 Allied Corporation Coaxial connector
DE3900736A1 (de) 1989-01-12 1990-07-26 Hoechst Ag Positiv arbeitendes strahlungsempfindliches gemisch enthaltend einen mehrfunktionellen (alpha)-diazo-(beta)-ketoester, verfahren zu dessen herstellung und strahlungsempfindliches aufzeichnungsmaterial enthaltend dieses gemisch
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
DE4014649A1 (de) 1990-05-08 1991-11-14 Hoechst Ag Neue mehrfunktionelle verbindungen mit (alpha)-diazo-ss-ketoester- und sulfonsaeureester-einheiten, verfahren zu ihrer herstellung und deren verwendung
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
SE9702772D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
WO1999025345A1 (en) 1997-11-14 1999-05-27 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
US6479531B1 (en) 1998-11-09 2002-11-12 James Black Foundation Limited Gastrin and cholecystokinin receptor ligands
GB2345058A (en) 1998-12-01 2000-06-28 Cerebrus Pharm Ltd Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system
HK1042701A1 (zh) 1998-12-25 2002-08-23 盐野义制药株式会社 具有hiv整合酶抑制活性的芳族杂环化合物
EP1297834A4 (en) 2000-06-14 2007-05-09 Shionogi & Co ENZYME INHIBITOR HAVING TWO DIVALENT METAL IONS AS ACTIVE CENTERS
ES2572030T3 (es) 2001-08-10 2017-07-19 Shionogi & Co., Ltd. Agente antiviral
WO2003030897A1 (en) 2001-10-03 2003-04-17 Ucb, S.A. Pyrrolidinone derivatives
DE122008000016I1 (de) 2001-10-26 2011-12-01 Angeletti P Ist Richerche Bio N-substituierte hydroxypyrimidinoncarboxamidhemmerder HIV-integrase.
WO2003042176A1 (en) 2001-11-13 2003-05-22 Shiseido Co., Ltd. Azabicyclo compound, matrix metalloprotease inhibitor, and skin preparation
WO2004004657A2 (en) 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Hiv integrase inhibitors
EP1549315A4 (en) 2002-09-11 2007-05-23 Merck & Co Inc DIHYDROXYPYRIDOPYRAZINE-1,6-DION COMPOUNDS AS HIV INTEGRASE INHIBITORS
SI1564210T1 (sl) 2002-11-20 2010-01-29 Japan Tobacco Inc 4-oksokinolinske spojine in njihova uporaba kot inhibitorji HIV integraze
DE602004014470D1 (de) 2003-01-14 2008-07-31 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
TW200528440A (en) 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
US20070155744A1 (en) 2004-01-30 2007-07-05 Istituto Di Ricerche Di Biologia Molecolare P, Angeletti S.P.A. N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4- carboxamide compounds useful as hiv integrase inhibitors
WO2005086700A2 (en) 2004-03-09 2005-09-22 Merck & Co., Inc. Hiv integrase inhibitors
WO2005110399A2 (en) 2004-04-29 2005-11-24 The Regents Of The University Of California Zinc-binding groups for metalloprotein inhibitors
EP1755586A2 (en) 2004-04-29 2007-02-28 The Regents of the University of California Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors
CN1964975B (zh) 2004-05-07 2011-11-30 默沙东公司 Hiv整合酶抑制剂
US7273859B2 (en) 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
US7531554B2 (en) 2004-05-20 2009-05-12 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as HIV integrase inhibitor
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
US8633219B2 (en) 2004-05-21 2014-01-21 Japan Tobacco Inc. Combination therapy
US7550463B2 (en) 2004-09-15 2009-06-23 Shionogi & Co., Ltd. Carbamoylpyridone derivatives having inhibitory activity against HIV integrase
WO2006066414A1 (en) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
JP5317257B2 (ja) 2005-02-21 2013-10-16 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する２環性カルバモイルピリドン誘導体
LT3284520T (lt) 2005-04-28 2019-09-25 Viiv Healthcare Company Policiklinis karbamoilpiridono darinys, turintis živ integrazę slopinantį poveikį
EP1888581A2 (en) 2005-05-16 2008-02-20 Gilead Sciences, Inc. Hiv-integrase inhibitor compounds
AU2006272521A1 (en) 2005-07-27 2007-02-01 Gilead Sciences, Inc. Antiviral phosphonate conjugates for inhibition of HIV
AU2006307101A1 (en) 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase
CA2847871C (en) 2005-12-30 2016-07-26 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
WO2007089030A1 (en) 2006-02-01 2007-08-09 Japan Tobacco Inc. Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection
AU2007223260C1 (en) 2006-03-06 2011-02-03 Japan Tobacco Inc. Method for producing 4-oxoquinoline compound
WO2007102499A1 (ja) 2006-03-06 2007-09-13 Japan Tobacco Inc. ４－オキソキノリン化合物の製造方法
US7893055B2 (en) 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors
US7888375B2 (en) 2006-07-19 2011-02-15 The University Of Georgia Research Foundation, Inc Pyridinone diketo acids: inhibitors of HIV replication
RS51864B (sr) 2006-09-07 2012-02-29 Industrial Research Limited Aciklični inhibitori amina nukleozid fosforilaza i hidrolaza
HRP20090213B1 (hr) 2006-09-12 2016-12-02 Gilead Sciences, Inc. Postupak i međuprodukti u pripravi inhibitora integraze
WO2008048538A1 (en) 2006-10-18 2008-04-24 Merck & Co., Inc. Hiv integrase inhibitors
EA019893B1 (ru) 2007-02-23 2014-07-30 Джилид Сайэнс, Инк. Фармацевтическая композиция и способ лечения вич-инфекции
US20080280945A1 (en) 2007-05-09 2008-11-13 Sachin Lohani Crystalline forms of an HIV integrase inhibitor
JP5547066B2 (ja) 2007-06-29 2014-07-09 ギリアード サイエンシーズ， インコーポレイテッド 治療用組成物およびその使用
JP5547067B2 (ja) 2007-06-29 2014-07-09 ギリアード サイエンシーズ， インコーポレイテッド 治療組成物およびその使用
WO2009018350A1 (en) 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Pyrone analog compositions and methods
AR068403A1 (es) 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
KR20100097156A (ko) 2007-11-16 2010-09-02 베링거 인겔하임 인터내셔날 게엠베하 사람 면역결핍 바이러스 복제의 억제제
GB0803019D0 (en) 2008-02-19 2008-03-26 Btg Int Ltd Fluorinated compounds
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2010011813A1 (en) 2008-07-23 2010-01-28 Alkermes, Inc. Complex of trospium and pharmaceutical compositions thereof
WO2010011819A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
KR101772610B1 (ko) 2008-07-25 2017-09-12 비이브 헬쓰케어 컴퍼니 화합물
EP2330902B1 (en) 2008-07-25 2012-11-14 GlaxoSmithKline LLC Chemical compounds
WO2010011815A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011818A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
PL2320908T3 (pl) 2008-07-25 2014-06-30 Viiv Healthcare Co Proleki dolutegrawiru
KR101682058B1 (ko) 2008-12-11 2016-12-02 비이브 헬쓰케어 컴퍼니 카르바모일피리돈 ｈｉｖ 인테그라제 억제제를 위한 제조방법 및 중간체
MX383683B (es) 2008-12-11 2025-03-11 Shionogi & Co Sintesis de inhibidores de integrasa de vih de carbamoil-piridona e intermediarios.
JP5697163B2 (ja) 2009-03-26 2015-04-08 塩野義製薬株式会社 置換された３−ヒドロキシ−４−ピリドン誘導体
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
JP5737691B2 (ja) 2009-06-15 2015-06-17 塩野義製薬株式会社 置換された多環性カルバモイルピリドン誘導体
WO2011028044A2 (ko) 2009-09-02 2011-03-10 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
ES2670811T3 (es) 2010-01-27 2018-06-01 Viiv Healthcare Company Terapia antivírica
NZ601847A (en) 2010-02-26 2014-03-28 Japan Tobacco Inc 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
WO2011139637A1 (en) 2010-05-03 2011-11-10 Philadelphia Health & Education Corporation Small-molecule modulators of hiv-1 capsid stability and methods thereof
MA34397B1 (fr) 2010-07-02 2013-07-03 Gilead Sciences Inc Dérivés d'acide napht-2-ylacétique dans le traitement du sida
NZ604716A (en) 2010-07-02 2014-12-24 Gilead Sciences Inc 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
WO2012009009A2 (en) 2010-07-14 2012-01-19 Addex Pharma S.A. Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
PT3127908T (pt) 2010-08-05 2019-02-04 Shionogi & Co Processo para preparar composto possuindo atividade inibidora de integrase do vih
WO2012039414A1 (ja) 2010-09-24 2012-03-29 塩野義製薬株式会社 置換された多環性カルバモイルピリドン誘導体のプロドラッグ
WO2012106534A2 (en) 2011-02-02 2012-08-09 The Regents Of The University Of California Hiv integrase inhibitors
AP2013007249A0 (en) 2011-04-21 2013-11-30 Gilead Sciences Inc Benzothiazole compounds and their pharmaceutical use
WO2012151361A1 (en) 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
WO2012151567A1 (en) 2011-05-05 2012-11-08 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for preventing and treating influenza
WO2013006738A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
US9206197B2 (en) 2011-09-14 2015-12-08 Mapi Pharma Ltd. Amorphous form of dolutegravir
BR112014008896A2 (pt) 2011-10-12 2017-04-18 Shionogi & Co derivado de piridona policíclico tendo atividade inibidora de integrase
CN104114559B (zh) 2011-12-12 2016-08-24 拜耳知识产权有限责任公司 氨基取代的咪唑并哒嗪
SG11201401189WA (en) 2012-04-20 2014-09-26 Gilead Sciences Inc Benzothiazol- 6 -yl acetic acid derivatives and their use for treating an hiv infection
WO2014008636A1 (en) 2012-07-11 2014-01-16 Merck Sharp & Dohme Corp. Macrocyclic compounds as hiv integrase inhibitors
EP2875024A4 (en) 2012-07-20 2015-12-23 Merck Sharp & Dohme HIV TREATMENT WITH AMIDOSUBSTITUTED PYRIMIDINONE DERIVATIVES
WO2014018449A1 (en) 2012-07-25 2014-01-30 Merck Sharp & Dohme Corp. Substituted naphthyridinedione derivatives as hiv integrase inhibitors
AU2013296289B2 (en) 2012-08-03 2017-10-05 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
CA2890983A1 (en) 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Heteroaryl substituted pyridyl compounds useful as kinase modulators
US9795619B2 (en) 2012-12-14 2017-10-24 Glaxosmithkline Llc Pharmaceutical compositions
WO2014099586A1 (en) 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
AU2013361401C1 (en) * 2012-12-21 2018-08-09 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US20140221355A1 (en) 2012-12-21 2014-08-07 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2014100077A1 (en) 2012-12-21 2014-06-26 Merck Sharp & Dohme Corp. Gastro-retentive formulations
AR094311A1 (es) 2012-12-27 2015-07-22 Japan Tobacco Inc Derivados de tetrahidroespiro-ciclopropil-pirido[1,2-a]pirazina inhibidores de la integrasa del hiv
US9951079B2 (en) 2013-06-13 2018-04-24 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
NO2865735T3 (cg-RX-API-DMAC7.html) * 2013-07-12 2018-07-21
EP3019503B1 (en) * 2013-07-12 2017-09-06 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
WO2015039348A1 (en) * 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
UA117499C2 (uk) 2013-09-27 2018-08-10 Мерк Шарп Енд Доум Корп. Заміщені похідні хінолізину, які можна використовувати як інгібітори інтегрази віл
US20150146340A1 (en) 2013-11-26 2015-05-28 Qualcomm Incorporated Multilayer ceramic capacitor including at least one slot
WO2015089847A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
EP3096763B1 (en) 2014-01-21 2019-12-25 Laurus Labs Limited Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof

Also Published As

Publication number Publication date
HK1246295A1 (en) 2018-09-07
AU2018236701B2 (en) 2020-04-30
US20220233525A1 (en) 2022-07-28
EP3252053A1 (en) 2017-12-06
ES2856867T3 (es) 2021-09-28
US20170128444A1 (en) 2017-05-11
DK3019499T3 (da) 2017-11-20
AU2020202368A1 (en) 2020-04-30
ES2647216T3 (es) 2017-12-20
AU2014286995A1 (en) 2016-03-03
AU2014286995B2 (en) 2018-10-18
HRP20171807T1 (hr) 2018-01-26
US20240238285A1 (en) 2024-07-18
HUE037343T2 (hu) 2018-08-28
JP2016525102A (ja) 2016-08-22
PL3019499T3 (pl) 2018-01-31
US11213523B2 (en) 2022-01-04
JP6411492B2 (ja) 2018-10-24
HK1223615A1 (en) 2017-08-04
US20150018359A1 (en) 2015-01-15
SI3252053T1 (sl) 2021-03-31
CA2918055A1 (en) 2015-01-15
US20200215062A1 (en) 2020-07-09
EP3019499B1 (en) 2017-09-06
CY1119545T1 (el) 2018-03-07
WO2015006733A1 (en) 2015-01-15
SI3019499T1 (sl) 2017-11-30
RS56539B1 (sr) 2018-02-28
US10456395B2 (en) 2019-10-29
US11883397B2 (en) 2024-01-30
PT3019499T (pt) 2017-11-24
LT3019499T (lt) 2017-11-27
US20190134028A1 (en) 2019-05-09
US9458159B2 (en) 2016-10-04
CA2918055C (en) 2018-01-23
EP3252053B1 (en) 2021-01-13
SMT201700525T1 (it) 2018-01-11
NZ716774A (en) 2021-03-26
EP3019499A1 (en) 2016-05-18
AU2018236701A1 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
BR112014017635A2 (cg-RX-API-DMAC7.html)
BR112014017659A2 (cg-RX-API-DMAC7.html)
BR112014017646A2 (cg-RX-API-DMAC7.html)
BR112014017638A2 (cg-RX-API-DMAC7.html)
AR092201A1 (cg-RX-API-DMAC7.html)
BR112014018871A2 (cg-RX-API-DMAC7.html)
BR112013027865A2 (cg-RX-API-DMAC7.html)
NO2865735T3 (cg-RX-API-DMAC7.html)
BR112014017634A2 (cg-RX-API-DMAC7.html)
BR112014017644A2 (cg-RX-API-DMAC7.html)
BR112014018950A2 (cg-RX-API-DMAC7.html)
BR112014017647A2 (cg-RX-API-DMAC7.html)
BR112014013184A8 (cg-RX-API-DMAC7.html)
BR112014017652A2 (cg-RX-API-DMAC7.html)
BR112015006860A2 (cg-RX-API-DMAC7.html)
BR112014017630A2 (cg-RX-API-DMAC7.html)
BR112014017627A2 (cg-RX-API-DMAC7.html)
BR112014017631A2 (cg-RX-API-DMAC7.html)
BR112014017641A2 (cg-RX-API-DMAC7.html)
BR112014020280A2 (cg-RX-API-DMAC7.html)
BR112014019880A2 (cg-RX-API-DMAC7.html)
BR112014020225A2 (cg-RX-API-DMAC7.html)
BR112014019465A2 (cg-RX-API-DMAC7.html)
BR112014017671A2 (cg-RX-API-DMAC7.html)
BR112014017636A2 (cg-RX-API-DMAC7.html)